相关实验视频
Updated: Jun 25, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
148
对于痴呆症诊断的β粉样蛋白PET扫描:CARE-IDEAS对实践和研究的影响
Terrie T Wetle1,2, Courtney H Van Houtven3,4,5, Megan E Shepherd-Banigan3,4,5
1Department of Health Services Policy and Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
Journal of the American Geriatrics Society
|May 27, 2024
概括
贝塔粉样蛋白PET扫描为阿尔茨海默病 (AD) 诊断提供了洞察力. 虽然结果是可以理解的,但它们的预后含义引起了混乱,强调了需要更好的患者和护理人员支持.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 生物标志物 生物标志物
背景情况:
- β-粉样蛋白PET扫描是阿尔茨海默病 (AD) 诊断的新兴生物标志物.
- 了解患者和护理人员对这些扫描的体验对于有效实施至关重要.
研究的目的:
- 探索β-粉样蛋白PET扫描结果对轻度认知障碍或痴呆症患者及其护理伙伴的动机,解释和影响.
- 确定改善沟通和支持资源的需求,与阿尔茨海默病护理中的PET扫描结果相关.
主要方法:
- 护理人员的反应和经验 (CARE) 研究,一个IDEAS补充,调查了患者和护理合作伙伴在基线和18个月.
- 对一小部分参与者进行了定性访谈.
- 医疗保险数据与调查信息合并以进行全面分析.
主要成果:
- 大多数参与者准确地报告了扫描结果,但难以理解预后影响.
- 尽管报告了一些痛苦,但没有观察到抑郁,负担或经济压力的显著变化.
- 参与者表达了对预后和支持资源的更多信息的强烈愿望.
结论:
- 需要有效的工具来讨论PET扫描的风险,好处和结果,以及加强支持资源.
- 利用扫描结果可以促进AD患者的共享决策和以人为中心的护理.
相关概念视频
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Positron Emission Tomography
4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K
Dementia
111
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
111
Imaging Studies II: Positron Emission Tomography and Scintigraphy
107
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
107

